** Shares of cancer test maker Exact Sciences fall 27.3% to $52 after the bell
** Cuts 2024 total revenue forecast; to be in the range of $2.73 bln to $2.75 bln vs prior estimate of $2.81 bln to $2.85 bln
** Company reports Q3 revenue of $709 mln, missing estimates of $717.7 mln, according to data compiled by LSEG
** Cuts revenue guidance for its screening segment to $2.08 bln to $2.1 bln from its prior guidance of $2.16 bln to $2.18 bln
** "Our execution during the third quarter and updated outlook for the full year don’t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong" - EXAS
** Up to last close, share are down 3.3% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。